On June 9, 2021, the board of the Chamber for Patent Disputes satisfied an invalidation action against the Eurasian patent 017084 on the territory of Russia concerning a combined drug for the treatment of diabetes type II, including, in particular, a combination of vildagliptin and metformin. Patent Attorneys Aleksey Zalesov and Natalia Samsonova represented the interests of the client — «KRKA» (Slovenia).
The invalidation action challenged the patentability requirements «industrial applicability», «novelty» and «inventive step». Earlier, the European patent analog was invalidated by the decision of the Opposition division of the European Patent Office due to the lack of novelty in the patented invention.
This decision provides new medicines access to the Russian market and reduces their cost which makes them more accessible to the consumer.